Introduction Psoriasis is a chronic inflammatory skin disease often associated with several
comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes …

Introduction The therapeutic armamentarium for the treatment of psoriasis, a chronic
inflammatory skin disease, is now reasonably broad and structured, with several therapeutic …

Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities,
such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular …

Simple Summary Psoriasis is a chronic multisystem inflammatory disease associated with a
wide range of comorbidities including cardiovascular disease, hypertension, diabetes …

Psoriasis is considered an autoimmune, inflammatory disorder with a genetic basis. The
underlying aetiology is yet unclear. Evidence suggests the congregation of immune cells …

Background: A comprehensive assessment of the risk-benefit profile of biologic agents in
psoriasis is lacking. We conducted a network meta-analysis of randomized trials on biologic …

Psoriasis is a systemic inflammatory disease. Effective management requires treatment with
agents targeting inflammation in skin, joints, and other tissues. Biologics for psoriasis are …

Background Approximately 2% of people worldwide have psoriasis, with as many as 1
million people with psoriasis in Canada alone. 1, 2 The severity of psoriasis ranges from …

Management of psoriasis is based on a stepwise approach that includes a wide variety of
treatment options. Our Drug review focusses on key points and recent advances in the …

Introduction Psoriasis is a common, chronic immune-mediated skin disease frequently
associated to inflammatory and metabolic comorbidities. About 20–30% of patients are …